MB 5029
Alternative Names: MB-5029Latest Information Update: 19 Jun 2024
At a glance
- Originator Must Bio
- Class Antineoplastics; Bispecific antibodies; Recombinant fusion proteins
- Mechanism of Action Programmed cell death 1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics, pharmacokinetics and adverse events data from the preclinical trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Preclinical trials in Solid tumours in South Korea (Parenteral) before April 2024 (Must Bio pipeline, May 2024)